Phase 3 Clinical Trials With Primary Completion Dates in April 2019
This is a list of Phase 3 trials with primary completion dates in April 2019 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ACST | Acasti Pharma, Inc. | 2019-04-01 | Phase 3 | NCT03398005 | A Phase 3 STudy of CaPRe In LOwering Very hiGh TriglYcerides (TRILOGY 1) |
| ACST | Acasti Pharma, Inc. | 2019-04-01 | Phase 3 | NCT03361501 | A Phase 3 STudy of CaPRe in LOwering Very hiGh TriglYcerides (TRILOGY 2) |
| ATNX | Athenex, Inc. | 2019-04-01 | Phase 3 | NCT03285490 | A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp (AK004) |
| ATNX | Athenex, Inc. | 2019-04-01 | Phase 3 | NCT03285477 | A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp |
| IRWD | Ironwood Pharmaceuticals, Inc. | 2019-04-01 | Phase 3 | NCT03573908 | A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation |
| OBSV | ObsEva SA | 2019-04-01 | Phase 3 | NCT03070951 | Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids |
| SNY | Sanofi | 2019-04-01 | Phase 3 | NCT03700242 | Imovax® Rabies and VERORAB® Immunogenicity and Safety After One Week 2-sites Intradermal or 1-site Intramuscular Pre-Exposure Prophylaxis Regimens, Followed by a Simulated Post-Exposure Prophylaxis Regimen at One Year |